NCT04866017
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT04866017 |
| Title | A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Patients With Stage III Unresectable Non-Small Cell Lung Cancer |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | BeiGene |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ESP | AUS |
CKB BOOST